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Chronic renal failure with gout: A marker of chronic lead poisoning.
EDTA (calcium disodium edetate) lead mobilization and x-ray fluores-
cence (XRF) finger bone lead tests were done in 42 patients with
chronic renal failure and without persisting lead intoxication. Nineteen
of 23 patients with gout and 8 of 19 without gout had positive EDTA
lead mobilization tests. Those patients with gout excreted significantly
more excess lead chelate than those without gout. In the gout group
17 patients denied any childhood or industrial exposure to lead. They
had a greater number of positive tests and excreted significantly more
excess lead chelate than 14 patients with neither gout nor lead expo-
sure. These results confirm that gout in the presence of chronic renal
failure is a useful marker of chronic lead poisoning. Of 27 patients with
positive lead mobilization tests, only 13 had elevated XRF finger bone
lead concentrations (sensitivity 48%). Three of 15 patients with nega-
tive lead mobilization tests had elevated XRF finger bone lead concen-
trations (specificity 80%). Although the XRF finger bone lead test is a
convenient noninvasive addition to the diagnostic evaluation of pa-
tients with chronic renal failure and gout, its application is limited due
to the lack of sensitivity of the method.
Insuffisance rénale chronique avec goutte: Un marqueur de
l'intoxication chronique au p10mb. Des tests de mobilisation du p10mb
par I'EDTA (edétate calcique disodique) et de fluorescence aux rayons
X (XRF) du p10mb dans une phalange ont été entrepris chez 42 malades
en insuffisance rénale chronique sans intoxication persistante au
p10mb. Dix neuf sur 23 malades atteints de goutte et 8 sur 19 sans
goutte avaient un test de mobilisation du p10mb par 1'EDTA positif.
Les malades goutteux excrétaient significativement plus de plomb
chélaté que les non goutteux. Dans le groupe atteint de goutte, 17
malades n'avaient eu aucune exposition au plomb dans l'enfance ou
dans l'industrie. us avaient un plus grand nombre de tests positifs et
excrétaient significativement plus de plomb chélaté que les 14 malades
sans goutte ni exposition au plomb. Ces résultats confirment que Ia
goutte au cours de l'insuffisance rénale chronique est un marqueur utile
de I'intoxication chronique au plomb. Parmi les 27 malades ayant des
tests de mobilisation du p10mb positifs, seulement 13 avaient une
élévation des concentrations de plomb dans la phalange par XRF
(sensibilité 48%). Trois des 15 malades avec des tests de mobilisation
du plomb négatifs avaient des concentrations de plomb dans Ia pha-
lange par XRF élevées (spécificité 80%). Bien que le test XRF pour le
plomb dans Ia phalange soit un complement pratique et non invasif
pour l'évaluation diagnostique des malades atteints d'insuffisance
rénale chronique avec goutte, son application est limitée en raison du
manque de sensibilité de Ia mCthode.
carbonate paint on verandahs of wooden houses [4], while
adult consumption of illegal moonshine whisky is often the
source in New Jersey [31 and other parts of the USA [5]. In
both countries a reliable history of lead exposure was some-
times lacking. In Queensland a childhood illness consistent
with acute lead poisoning in either the patient or in a sibling
has been regarded as evidence of childhood lead exposure [21.
Recovery from supposed acute lead poisoning was followed by
a chronic form of nephritis, lead nephropathy [61. Approxi-
mately 50% of Queensland patients with lead nephropathy de-
velop gout [7], while gout in the presence of renal failure was
the criterion for entry into the New Jersey study.
The EDTA (calcium disodium edetate) lead mobilization test
is regarded as the most reliable clinical method for demonstrat-
ing excessive past lead absorption [7—10]. A newer, noninva-
sive and less time-consuming method is that of x-ray fluores-
cence (XRF) which measures in vivo the lead concentration in
bone [11, 12].
This study re-examines the importance of gout in the pres-
ence of chronic renal failure as a marker of chronic lead poi-
soning and examines the value of XRF as a screening test in
patients suspected of having chronic lead poisoning.
Methods
Patients. Forty-two patients with chronic renal failure
(plasma creatinine concentration  0.13 mmoles/liter) were
studied. To our knowledge, none of the patients had been ex-
posed recently to lead and all had whole blood lead concen-
trations well within the normal range for our laboratory. Each
gave written informed consent. Twenty-three subjects (seven
males) gave a history of at least one episode of acute gout, con-
sisting invariably of acute monoarticular arthritis of the first
metatarso-phalangeal joint (Table 1). In six of these 23 there
had been exposure to lead in childhood in either the patient
(four patients) or in a sibling (two patients). The mean age of
the 23 patients was 63.5 5.8 years (range, 54 to 77). The
mean plasma creatinine was 0.6 0.35 mmole/liter (range,
0.13 to 1.58). Nineteen patients (five males) with chronic renal
Lead has been implicated as the underlying cause of renal
damage in clinical studies from Queensland, Australia [1, 2]
and from New Jersey, United States of America (USA) [3]. In
Queensland, children were exposed to weathered white lead
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Table 1. Details of patients with gout
Plasma Plasma XRF Excess
creatinine urate bone lead
Patient lead
no. Sex Age mmo!eslliter pg/g
Baseline
urine lead
Peak
urine lead
Lead
exposuremo!es
M 77 0.31 0.54 103 36.8 0.15 29.8 Yes
2 F 64 0.49 0.40" ND 18.2 0.12 7.39 No
3 M 54 0.51 0.56 128 17.8 0.10 6.56 Yes
4 F 59 0.44 0.31" 29 12.5 0.18 4.66 No
5 F 63 0.77 0.58 ND 11.4 0.22 5.12 No
6 F 55 0.66 0.50" ND 09.6 0.04 3.53 Yes
7 F 70 0.21 0.50 ND 09.5 0.25 5.82 No
8 M 60 0.56 0.59 38 08.2 0.10 2.68 No
9 F 58 0.43 0.37a ND 07.6 0.19 2.87 No
10 M 56 0.79 0.47a ND 06.5 2.39 5.72 No
11 F 68 0.57 0.63 121 05.3 0.12 3.01 No
12 F 64 0.38 0.46 ND 05.1 0.10 2.40 Yes
13 F 63 0.98 0.55 80 04.9 0.27 2.30 No
14 F 64 0.66 0.42a ND 04.3 0.03 2.30 No
15 F 60 0.41 0.56 53 04.1 0.08 2.61 Yes
16 F 63 0.25 0.64 59 03.9 0.11 2.40 No
17 M 63 1.58 0.62a ND 03.7 0.33 3.20 No
18 F 75 0.97 0.59 ND 03.0 0.09 1.40 Yes
19 F 58 0.83 0.31" ND 03.0 0.05 1.01 No
20 F 66 0.53 0.62" ND 02.7 0.05 1.17 No
21 M 67 1.18 0.57 ND 01.9 0.08 0.63 No
22 M 67 0.18 0.33a ND 01.7 0.05 1.16 No
23 F 67 0.13 0.21a 25 0.9 0.24 0.88 No
Mean 63.5 0.60 0.49 7.94 0.23 4.29
SD 5.8 0.35 0.12 7.87 0.48 5.88
Abbreviation: ND, not detectable; XRF, x-ray fluorescence.
"Allopurinol.
Table 2. Details of patients without gout
Plasma Plasma XRF Excess Baseline Peak
creatinine urate bone lead
Patient lead
no. Sex Age mmoles/Iiter p.glg
urine lead urine lead
Lead
exposure,umo1es
M 57 0.18 0.35 62 17.3 0.16 9.38 Yes
2 F 63 0.70 0.51 40 12.9 0.08 4.65 Yes
3 F 54 0.60 0.42 ND 10.2 0.28 7.21 Yes
4 M 49 0.32 0.40 38 06.6 0.24 3.30 No
5 F 48 0.65 0.57 ND 06.1 0.06 3.73 No
6 F 66 0.22 0.55 40 05.7 0.02 3.31 Yes
7 F 66 0.23 0.40 29 05.5 0.17 3.78 No
8 M 61 0.62 0.45 ND 03.0 0.74 1.95 No
9 F 54 0.93 0.52 ND 02.8 0.21 1.35 No
10 F 68 0.99 0.54 ND 02.3 0.10 0.94 No
11 F 60 0.92 0.57 ND 01.9 0.07 0.78 No
12 F 58 0.16 0.50 ND 01.9 0.36 1.34 Yes
13 F 60 0.60 0.37 ND 01.8 0.09 0.83 No
14 F 65 0.18 0.40 ND 01.5 0.04 0.79 No
15 M 48 0.41 0.57 ND 01.1 0.23 0.90 No
16 F 59 0.28 0.48 ND 00.9 0.12 0.49 No
17 F 59 0.13 0.40 26 00.9 0.08 0.89 No
18 F 52 0.28 0.48 ND 00.8 0.19 0.66 No
19 M 61 1.03 0.45 30 00.1 0.05 0.09 No
Mean 58.3 0.50 0.47 4.38 0.17 2.44
SD 6.1 0.31 0.07 4.63 0.16 2.48
Abbreviation: ND, not detectable; XRF, x-ray fluorescence.
failure without a history of gout were selected as control sub- age of the 19 patients was 58.3 6.1 years (range, 48 to 68).
jects (Table 2). In five there was a history of childhood lead ex- The mean plasma creatinine concentration was 0.5 0.31
posure, in the patient (two) or in a sibling (three). The mean mmole/liter (range, 0.13 to 1.03). While the patients with gout
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were significantly older (t = 2.81; 2P < 0.01), their mean
plasma creatinine did not differ significantly from that of the pa-
tients without gout. The mean plasma urate concentration was
not significantly higher in those patients with gout compared
with those without gout (0.49 0.12 mmole/Iiter; 0.47 0.07
mmole/liter). However, 11 of the 23 patients with gout were be-
ing treated with allopurinol. When the values from these pa-
tients were excluded, the difference became significant (mean,
0.56 0.05 mmole/liter; t = 3.95, 2P < 0.001).
Bone lead detection system. The bone lead detection system
utilizes x-ray fluorescence (XRF). Characteristic x-rays ex-
cited by 122 keV photons emitted from Co-57 sources 1111 are
detected by a 13.5% Ge(Li) system 1121. The measurement in-
volves irradiation of the middle phalanx of the index finger.
Lead concentration is standardized using results from finger-
like phantoms containing known concentrations of lead. The
absorbed dose to the finger is approximately 5 mGy (500 mrad)
whereas whole body and gonad doses are negligible. The mini-
mum detection limit is 25 .tg Pb/g bone for 1000 sec of irradia-
tion time.
EDTA lead excretion test. The EDTA test was performed as
follows: Twenty-four-hour urine lead excretion was measured
on each of six consecutive days with 1 g of EDTA given intra-
venously in 250 ml of 5% dextrose over 1 hr, 6 hr into day 3.
Excess lead excretion was calculated by subtracting twice the
amount excreted on control days 1 and 2 from the sum ex-
creted on days 3, 4, 5, and 6. In the presence of renal failure
the excretion of the lead chelate is delayed, but the amount of
excess lead remains less than 2.9 tmoles in unexposed per-
sons [7].
Biochemical methodology. Urinary lead was measured by
atomic absorption spectrophotometry (Varian Techtron Model
AA6 equipped with a Carbon Rod Atomiser Model 63; Walnut
Creek, California, USA). Plasma creatinine and urate were de-
termined by standard Technicon SMAC procedures.
Statistical methods. Mean values are reported SD. Data
were analyzed by the Mann-Whitney U-test, x2 test, Fisher's
exact test, least squares correlation coefficient, sensitivity, and
specificity.
Results
Nineteen of the 23 patients with gout had positive EDTA
lead mobilization tests compared with 8 of the 19 patients with-
out a history of gout (x2, P 0.016, Tables I and 2). The mean
value of 7.94 7.87 moles for the gout group was signifi-
cantly higher than that of 4.38 4.63 moles for the non-gout
group (Mann-Whitney U-test 2P < 0.05).
Of 27 patients with positive EDTA lead mobilization tests,
13 had elevated XRF finger bone lead concentrations (Fig. 1).
The sensitivity of the XRF test was 48%. Three patients with
negative EDTA mobilization tests had elevated XRF finger
bone lead concentrations. The specificity of the XRF test was
80%. Thus, a total of 16 patients had detectable XRF finger
bone lead. These levels showed a significant positive correla-
tion with the excess EDTA lead values (Fig. 2).
The 11 patients with a history of childhood lead exposure ex-
creted 11.31 10.07 p.moles (range, 1.9 to 36.8) of excess lead
chelate compared with 4.56 4.07 /Lmoles (range, 0.1 to 18.2)
excreted by the remaining 31 (Mann-Whitney 2P < 0.01). Six
of these 11 patients had gout. All six had elevated EDTA lead
mobilization tests (N = 6; mean, 12.73 12.98 imoles; Table
3). Three of the six had elevated XRF finger bone lead concen-
trations (128, 103; 53 JLg/g). Four of the five patients without
gout but with a history of childhood lead exposure had posi-
tive EDTA lead mobilization tests (N = 4; mean, 9.6 6.02
tmo1es), while three of the five had elevated XRF finger bone
lead concentrations (62, 40, 40 gIg). The mean excess EDTA
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Fig. 1. Shows the XRF finger bone lead
concentrations (.tgIg) of the 27 patients with
positive EDTA lead mobilization tests (2.9
j.tmoles or greater of excess lead chelate). ND
signifies not detectable.
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+Gout +Gout —Gout —Gout
+ History
—History + History —History Total
Positive
EDTA
Test 6 13 4 4 27
Negative
EDTA
Test 0 4 1 10 15
Total 6 17 5 14 42
lead value did not differ significantly between the groups. All
11 patients with childhood lead exposure had lived in Queens-
land throughout their childhood.
There were 17 patients with gout but without known child-
hood lead exposure. Only one had lived outside Queensland
during childhood. Thirteen of the 17 had a positive EDTA lead
mobilization test (N = 13, mean 6.25 4.57 moles) and six
had elevated XRF finger bone lead concentrations (121, 80, 59,
38, 29, 25 xg/g). There were 14 patients who had neither gout
nor a history of childhood lead exposure. Of these, only four
(three with a Queensland childhood) had a positive lead excre-
tion test (N = 4, mean 2.52 2.09 jmoles). Four of the 14
had elevated XRF finger bone lead concentration (38, 30, 29,
26 gIg).
Finally, of the patients without a history of lead exposure,
those with gout mobilized significantly more excess EDTA lead
than those without gout (Mann-Whitney 2P < 0.01).
There were five patients who did not spend their childhood
in Queensland, four not in Australia. Of these, two had a posi-
tive EDTA lead mobilization test (5.5, 3.7 xmoles). Twenty-
five of the 37 patients who spent their childhood in Queens-
land had a positive EDTA lead mobilization test (Fisher's exact
test, P = 0.19. This is not significant.). All 37 recalled living in
wooden (painted) houses with open verandahs.
No significant correlation was found between the plasma cre-
atinine concentration and the amount of lead mobilized follow-
ing EDTA, neither the peak urine lead nor the calculated ex-
cess lead. This lack of correlation existed for all 42 patients and
for the 23 with gout. The peak urine lead concentration but not
the baseline lead concentration showed a significant positive
correlation with the calculated excess amount of lead chelate
(r = 0.94, 2P < 0.001).
Discussion
This study confirms findings from Queensland and New Jer-
sey that gout in the presence of chronic renal failure is a marker
of chronic lead poisoning [2, 3]. Those patients with gout ex-
creted significantly more excess lead chelate than those with-
out gout. Nineteen of 23 patients with gout had a positive
EDTA lead mobilization test compared with 8 of 19 patients
without gout. In a similar group of patients with gout and
chronic renal failure, the New Jersey investigators found 16
positive out of 22 tested [31. The four patients with gout who
had a negative EDTA lead mobilization test may have had pri-
mary gout, although hyperuricemia and gout rarely result in
kidney damage unless other renal disease supervenes [13] or
hypertensive vascular disease is present [141. Two of the four
had the lowest plasma creatinine concentrations of the entire
group. The disproportionate hyperuricemia of chronic lead
nephropathy has been postulated to be due to excessive tubu-
lar reabsorption of urate [151. In previous clinical studies from
Queensland 50% of patients with lead nephropathy were noted
to have gout and, unlike primary gout where there is a predom-
inance of males, this incidence was the same in females as in
males [2]. In the present study 70% of patients with positive
EDTA lead mobilization tests had gout and 74% were female.
Although the high proportion of gout patients receiving al-
lopurinol made it difficult to determine if a disproportionate
hyperuricemia existed, the patients with gout not on allopuri-
nol did have a significantly higher plasma urate than those pa-
tients without gout. The predominance of females may reflect
a bias in the selection process (a female with gout suggests un-
derlying chronic lead poisoning more than a male with gout) or
the greater longevity of the female. This was not seen in a
retrospective study of 1900 necropsies from The Royal Bris-
bane Hospital between 1975 and 1980 [16]. Twenty-three pa-
tients were found with chronic lead nephropathy. The criteria
for this diagnosis were bilateral symmetrically contracted kid-
neys and bone lead concentration greater than 50 .tg/g (ash
weight) [17]. This group comprised 13 men and 10 women,
ranging in age from 35 to 75 years (mean age, 60).
In the gout group 17 patients denied any childhood or indus-
trial exposure to lead. When their EDTA lead mobilization test
results were compared with those of 14 patients with neither
gout nor lead exposure, more had positive tests and signifi-
cantly more lead chelate was excreted. Four of the eight pa-
tients with positive lead mobilization tests who did not have
gout did have a history of childhood lead exposure. Ten of the
11 patients with such a history had positive lead mobilization
tests, six of the 11 had gout. Thus, gout and childhood lead ex-
posure were both useful markers of chronic lead poisoning.
The absence of both markers did not rule out the possibilty of
a patient having chronic lead poisoning, as demonstrated by
four patients. In New Jersey, two separate studies in patients
with gout [3] and hypertension [18] have found that patients'
recollections of past lead exposure did not coincide with the as-
sessment of body stores of lead provided by the EDTA lead
mobilization test.
The non-invasive XRF technique has the advantage of sim-
plicity and speed of operation. Ahlgren and Mattson [11] re-
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Fig. 2. Shows the relationship of the calculaied excess 4-day urinary
lead following EDTA to the detectable XRF finger bone lead concen-
tration ( 25 g/g); (r = 0.52; P < 0.05).
Table 3. Chronic lead poisoning: the relationship with gout and
history of childhood lead poisoning
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ported the minimum detectable lead concentration of finger
bone to be 14 gIg for 15 mm measuring time or 20 tg/g for 40
mm of measurement [19]. These authors recorded bone lead
concentrations of 50 5 .rgIg in five retired metal workers and
detectable lead in 15 of 22 industrial workers, range 20 to 118
g/g [191. We identified 13 of 27 patients with positive EDTA
lead mobilization tests as having elevated finger bone lead con-
centrations. Three patients with negative EDTA lead mobili-
zation tests had detectable XRF finger bone lead concentra-
tions. The mean of the 16 XRF values was 56 34 g/g with
a range of 25 to 128 .rg/g. A positive correlation was found with
excess EDTA lead excreted. However, our XRF method failed
to detect lead in 14 patients with positive EDTA lead mobili-
zation tests, including three of six patients with gout and a his-
tory of childhood lead exposure. One possible explanation for
this lack of sensitivity is the non-uniform distribution of lead
in the skeleton.
It is the practice in Queensland to use skull bone for the post-
mortem bone lead concentration, because of its higher lead
content than rib bone in both normal subjects (19 vs. 11.8 g/g)
and in patients with lead nephropathy [20]. The difference of
concentrations of lead between long and flat bone also has been
noted [21], tibia having two to three times that of rib. The turn-
over rate for the skeleton, based on Strontium-90 concentra-
tions in total adult skeletons from New York City is about 3.5%
per annum [22]. The turnover rate of vertebrae is about 8% per
annum and that for the midshafts of femora is about 1.5% per
year, these being regarded as the skeletal components with
fastest and slowest turnover rates. According to Rivera [22],
the total skeleton can be thought of as consisting of 30% ver-
tebrae-like bone and 70% femur-shaft-like bone. Secondary
hyperparathyroidism would be expected to increase further the
turnover of bone and not uncommonly leads to subperiosteal
erosions and cyst formation in the bones of the fingers. For this
reason, finger bone may indeed have been the wrong bone to
use particularly if its bone turnover rate approaches that of ver-
tebra rather than that of femur or skull.
Three patients with gout and positive EDTA lead mobiliza-
tion tests have come to autopsy (2, 10, 19 in Table I). All three
had undetectable XRF finger bone lead concentrations. Rib
was the only bone available for analysis in patient 19 whose
lead concentration was 60 tg/g. The lead concentration in skull
bone was higher than in rib bone for patients 2 and 10 (70 and
95 vs. 40 and 80 g/g). The normal range for skull bone is 30
to 50 tg/g.
A group of 200 Queensland adults without known health
problems have also had XRF finger bone lead concentrations
measured [23]. Forty of these subjects had detectable levels of
25 g/g or more. There were significant correlations between
childhood residence in a painted wooden house and raised lev-
els, and between occupational exposure and raised levels. In
the present study all of the patients who spent their childhood
in Queensland recalled living in wooden (painted) houses with
open verandahs.
In conclusion, gout has proven to be a useful marker of
chronic lead poisoning. In the presence of chronic renal failure
XRF lead measurements using a finger bone lack sensitivity.
Measurement in a long bone with slow bone turnover such as
the tibia may improve sensitivity.
Acknowledgments
This study was supported in part by a grant from the National Health
and Medical Research Council of Australia. We thank scientists E.
Low and V. Summers for assistance with the lead measurements. Dr.
R. Mortimer helped with the final draft of the paper.
Reprint requests to Dr. P. Craswe/l, Department qf Nephrology,
Royal Brisbane Hospital, Queensland, Australia 4029
References
1. NYE LJJ: An investigation of the extraordinary incidence of
chronic nephritis in young people in Queensland. Med J Aust
2:145—159, 1929
2. EMMER5ON BT: Chronic lead nephropathy. Kidney mt 4:1—5. 1973
3. BATUMAN V, MAESAKA JK, HADDAD B, TEPPER E, LANDY E.
WEDEEN RP: The role of lead in gout nephropathy. N Engl J Med
304:520—523, 1981
4. HENDERSON DA: The etiology of chronic nephritis in Queensland.
Med fAust 1:377—386, 1958
5. MORGAN JM, HARTLEY MW, MILLER RE: Nephropathy in chronic
lead poisoning. Arch Intern Med 118:17—29, 1966
6. INGLI5 JA, HENDERSON DA, EMMER5ON BT: The pathology and
pathogenesis of chronic lead nephropathy occurring in Queens-
land.JPatho/ 124:65—76, 1978
7. EMMERSON BT: Chronic lead nephropathy: The diagnostic use of
calcium EDTA and the association with gout. Aust Ann Med
12:310—324. 1963
8. EMMERSON BT, TI-IIELE BR: Calcium versenate in the diagnosis of
chronic lead nephropathy. Med J Aust 1:243—248, 1960
9. MORGAN JM, BURCH HB: Comparative tests for diagnosis of lead
poisoning. Arch Intern Med 130:335—340, 1972
10. WEDEEN RP, MAESAKA JK. WEINER B, LIPAT GA, LYoNs MM,
VITALE LF, JosELow MM: Occupational lead nephropathy. Am J
Med 59:630—641, 1975
11. AHLGREN L, MATT55ON S: An x-ray fluorescence technique for in-
vivo determination of lead concentration in a bone matrix. Phys
Med Biol 24:136—145, 1979
12. THOMAS BJ, THOMAS BW, DAvEY iF, BADDELEY H, SUMMERS V,
CRASwELL P: The in-vivo detection of the toxic heavy elements.
lead and cadmium. Tech Rep SerIAEA, in press, 1984
13. Yu TF, BERGER L, DORPH DJ, SMITH H: Renal function in gout.
V. Factors influencing the renal haemodynamics. Am J flied
67:766—771, 1979
14. Yu TF. BERGER L: Impaired renal function in gout: Its associa-
tion with hypertensive vascular disease and intrinsic renal disease.
Am J Med 72:95—100, 1982
15. EMMERSON BT, MIROSCH W, DOUGLAS JB: The relative contri-
butions of tubular reabsorption and secretion to urate excretion in
lead nephropathy. Aust NZ J Med 4:353—362, 1971
16. SEARLE J, CRASWELL P. BOYLE P, Low KL: The current status
of chronic lead nephropathy in Queensland (abstract). Aust NZ J
Med 11:600—601, 1981
17. HENDERSON DA, INGus JA: The lead content of bone in chronic
Bright's Disease. Australas Ann Med 6:145—154, 1957
18. BATUMAN V LANDY E, MAESAKA JK, WEDEEN RP: Contribu-
tion of lead to hypertension with renal impairment. N EngI J Med
309:17—21, 1983
19. AHLGREN L, HAEGER-ARONSEN B, MATTSSON S, SCIIUTZ A: In-
vivo determination of lead in the skeleton after occupational ex-
posure to lead. Br J lad Med 37:109—113, 1980
20. HENDERSON DA: A follow-up of cases of plumbism in children.
Austra/as Ann Med 3:219—224, 1954
21. BARRY PSI, MOSSMAN DB: Lead concentrations in human tissues.
Br J md Med 27:339—351, 1970
22. RIVERA J: Human bone metabolism inferred from fall-out inves-
tigations. Nature 207: 1330-1332, 1965
23. PRICE J, BADDELEY H, KENARDY JA, THOMAS BJ, THOMAS BW:
In vivo x-ray fluorescence estimation of bone lead concentrations
in Queensland adults. Br J Radial 57:29—33, 1984
